Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncternal Therapeutics (ONCT) and 180 Life Sciences (ATNF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncternal Therapeutics (ONCTResearch Report) and 180 Life Sciences (ATNFResearch Report).

Oncternal Therapeutics (ONCT)

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Oncternal Therapeutics, with a price target of $3.50. The company’s shares closed last Wednesday at $1.12, close to its 52-week low of $0.69.

According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -38.5% and a 15.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncternal Therapeutics with a $8.50 average price target, implying a 665.8% upside from current levels. In a report issued on August 9, Brookline Capital Markets also maintained a Buy rating on the stock with a $12.00 price target.

See today’s best-performing stocks on TipRanks >>

180 Life Sciences (ATNF)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Hold rating on 180 Life Sciences. The company’s shares closed last Wednesday at $1.10, close to its 52-week low of $0.79.

According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -29.3% and a 28.1% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Clarus Therapeutics Holdings, and Vertex Pharmaceuticals.

The the analyst consensus on 180 Life Sciences is currently a Hold rating.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ONCT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos